New Training Tools for Innovative Approaches to Oral Health Care

Topic: 
Publish Date: 
Wednesday, January 29, 2014
According to various studies, 58 to 64 percent of people living with HIV (PLWH) do not receive regular dental care, even though oral health is a critical component of total health for all people. In fact, PLWH are more likely to have an unmet need for oral health care than for medical care. PLWH also experience a high incidence of oral health problems in general, as well as those directly related to HIV infection. Between 32 and 46 percent of PLWH will have at least one major HIV-related oral health problem in their lifetime.

Free, Web-Based Tool Saves Time for Case Managers and Clients

Publish Date: 
Wednesday, January 15, 2014
Grantees, providers, and clients alike are all facing daunting challenges of having to “do more with less.” Identifying and utilizing tools that can save time, reduce errors, and provide higher quality care are important strategies for those who care for the most vulnerable and underserved people living with HIV/AIDS (PLWHA).

Prevention & Early Detection of Oral Cancer: A Professional Responsibility

Topic: 
Publish Date: 
Friday, December 13, 2013
According to American Cancer Society, over 30,000 Americans are diagnosed with oral cancer (oral cavity and oropharynx) each year, the majority of whom are men over the age of 60. The mortality rate from oral cancer exceeds that of cervical cancer and results in one person dying from the disease or its complications every hour.

Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB) Graduate/Health Profession Training Programs

Publish Date: 
Wednesday, November 27, 2013

With only about one-quarter of Americans living with HIV being virally suppressed, more Americans becoming newly infected each year, and an aging cohort of HIV specialty care providers (who started providing care to HIV infected persons in the 1980’s), it is essential that health professional training programs incorporate curricula and experience regarding HIV prevention, diagnosis, care, and treatment.   

Cobicistat as a PK Booster of Atazanavir

Publish Date: 
Friday, October 5, 2012

Cobicistat is a derivative of ritonavir and a potent inhibitor of CYP3A. As does ritonavir, it "boosts" blood levels of other substrates of this enzyme but, unlike ritonavir, it has no activity against HIV. It has been developed as a pharmacokinetic enhancer of the integrase inhibitor elvitegravir and of some PIs.

Interactions with Hepatitis C Protease Inhibitors

Publish Date: 
Wednesday, May 1, 2013

Rilpivirine and Boceprevir

Boceprevir (BOC) is a hepatitis C virus (HCV) NS3/4A protease inhibitor used in combination with pegylated interferon + ribavirin for the treatment of HCV. As BOC is an inhibitor of hepatic cytochrome (CYP) 3A4, and many protease inhibitors and NNRTIs affect or are affected by this hepatic isoenzyme, interactions are expected.

Pitavastatin and Darunavir/Ritonavir

Publish Date: 
Friday, October 5, 2012
Treatment of dyslipidemia is often complicated by drug interactions between statins and antiretrovirals. Pitavastatin is one of the newer statins approved and is one of the few that is not metabolized primarily by the CYP450 3A4 pathway. It is predominantly metabolized via glucuronidation and so, theoretically, is less likely to interact with NNRTIs or PIs.

More on Protease Inhibitors and Corticosteroids

Publish Date: 
Friday, May 18, 2012

It has been demonstrated previously that ritonavir significantly increases serum levels of inhaled and intranasal fluticasone and that coadministration with fluticasone should be avoided. Few studies have examined interactions between PIs and other corticosteroids. At the 19th Conference on Retroviruses and Opportunistic Infections, researchers presented results from a randomized controlled PK study of interactions of both darunavir/ritonavir and ritonavir (alone) with inhaled beclomethasone.[1] 

Dolutegravir Receives FDA Approval

Publish Date: 
Monday, October 7, 2013
The integrase inhibitor dolutegravir (brand name: Tivicay) was approved by the U.S. Federal Drug Administration in August, for use in treatment-naive and treatment-experienced adults, as well as for children aged ≥12 years (and weight ≥40 kg) who have not previously taken integrase inhibitors.

Pages

Subscribe to Sharespot RSS feed